238 related articles for article (PubMed ID: 22252093)
21. The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children.
Biss TT; Avery PJ; Williams MD; Brandão LR; Grainger JD; Kamali F
J Thromb Haemost; 2013 Feb; 11(2):373-5. PubMed ID: 23279643
[No Abstract] [Full Text] [Related]
22. Pharmacogenetics role in the safety of acenocoumarol therapy.
Jiménez-Varo E; Cañadas-Garre M; Henriques CI; Pinheiro AM; Gutiérrez-Pimentel MJ; Calleja-Hernández MÁ
Thromb Haemost; 2014 Sep; 112(3):522-36. PubMed ID: 24919870
[TBL] [Abstract][Full Text] [Related]
23. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
[TBL] [Abstract][Full Text] [Related]
24. Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients.
Krishna Kumar D; Madhan S; Balachander J; Sai Chandran BV; Thamijarassy B; Adithan C
Thromb Res; 2013 Apr; 131(4):363-7. PubMed ID: 23473641
[TBL] [Abstract][Full Text] [Related]
25. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.
Santos PC; Dinardo CL; Schettert IT; Soares RA; Kawabata-Yoshihara L; Bensenor IM; Krieger JE; Lotufo PA; Pereira AC
Eur J Clin Pharmacol; 2013 Apr; 69(4):789-97. PubMed ID: 22990331
[TBL] [Abstract][Full Text] [Related]
26. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
Daly AK
Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
[TBL] [Abstract][Full Text] [Related]
28. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
van Schie RM; Wessels JA; le Cessie S; de Boer A; Schalekamp T; van der Meer FJ; Verhoef TI; van Meegen E; Rosendaal FR; Maitland-van der Zee AH;
Eur Heart J; 2011 Aug; 32(15):1909-17. PubMed ID: 21636598
[TBL] [Abstract][Full Text] [Related]
29. Patients benefit from genetics-guided coumarin anticoagulant therapy.
Maitland-van der Zee AH; Daly AK; Kamali F; Manolopoulous VG; Verhoef TI; Wadelius M; de Boer A; Pirmohamed M;
Clin Pharmacol Ther; 2014 Jul; 96(1):15-7. PubMed ID: 24942396
[TBL] [Abstract][Full Text] [Related]
30. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
[TBL] [Abstract][Full Text] [Related]
31. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
32. Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.
Lacut K; Ayme-Dietrich E; Gourhant L; Poulhazan E; Andro M; Becquemont L; Mottier D; Le Gal G; Verstuyft C
Br J Clin Pharmacol; 2012 Mar; 73(3):428-36. PubMed ID: 21883387
[TBL] [Abstract][Full Text] [Related]
33. Extreme sensitivity to acenocoumarol therapy in patient with both VKORC.-1639 A/A and CYP2C9*1/*3 genotypes.
Kovac MK; Rakicevic LB; Radojkovic DP
J Thromb Thrombolysis; 2011 Oct; 32(3):368-71. PubMed ID: 21638223
[TBL] [Abstract][Full Text] [Related]
34. Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.
Smires FZ; Moreau C; Habbal R; Siguret V; Fadili S; Golmard JL; Assaidi A; Beaune P; Loriot MA; Nadifi S
J Clin Pharm Ther; 2012 Oct; 37(5):594-8. PubMed ID: 22486182
[TBL] [Abstract][Full Text] [Related]
35. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
[TBL] [Abstract][Full Text] [Related]
36. A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9.
Rettie AE; Farin FM; Beri NG; Srinouanprachanh SL; Rieder MJ; Thijssen HH
Br J Clin Pharmacol; 2006 Nov; 62(5):617-20. PubMed ID: 16869821
[TBL] [Abstract][Full Text] [Related]
37. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
[TBL] [Abstract][Full Text] [Related]
38. CYP2C9 and VKORC1 gene polymorphism is inessential for bleeding development under conditions of oral application of anticoagulant acenocoumarol in Russian patients at high risk of thromboembolic complications.
Sychev DV; Ignatyev IV; Emelyanov NV; Milovanova VV; Kossovskaya AV; Kukes IV; Tashenova AI; Kukes VG
Bull Exp Biol Med; 2012 Oct; 153(6):886-8. PubMed ID: 23113310
[TBL] [Abstract][Full Text] [Related]
39. Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.
Gschwind L; Rollason V; Boehlen F; Rebsamen M; Combescure C; Grünenwald M; Matthey A; Bonnabry P; Dayer P; Desmeules JA
Pharmacogenomics; 2013 May; 14(7):745-53. PubMed ID: 23651023
[TBL] [Abstract][Full Text] [Related]
40. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.
Schalekamp T; Brassé BP; Roijers JF; van Meegen E; van der Meer FJ; van Wijk EM; Egberts AC; de Boer A
Clin Pharmacol Ther; 2007 Feb; 81(2):185-93. PubMed ID: 17192772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
